
    
      This is a non-interventional, cross-sectional, multicentre, observational study to be
      conducted at 15 sites from different geographical regions across India. The study targets to
      enrol 240 patients with nearly 16 patients per site over 6 months. The study will enrol
      females with diagnosis of ovarian, primary peritoneal, or fallopian tube cancer. No study
      medication will be prescribed or administered as a part of study procedure.

      The study will start only after obtaining written approval of Independent Ethics Committee
      (IEC) / Institutional Review Board (IRB) and written informed consent of the patient.

      The study will start only after obtaining written approval of Independent Ethics Committee
      (IEC) / Institutional Review Board (IRB) and written informed consent of the patient.
      Eligible patients will undergo physical examination and data of demographics, vital signs,
      present/ past history of illness, family history of breast/ovarian cancer, current and
      previous chemotherapy regimen and current medication will be collected.
    
  